Why is Moderna stock down today?

Traders Union
All News
Financial News
Moderna slides 2.75% today to $46.42

Highlights

Capital World Investors initiated a major position in Moderna during Q4, acquiring 12.8 million shares valued at $378.3 million.
Moderna advanced its pipeline with positive Phase 2 maternal RSV data, UK approval for a cancer prevention vaccine trial, and global R&D expansion.
Moderna trades under key short- and medium-term averages with bearish daily momentum, but is likely to move within a $44.30 to $49.60 range over the next week.

Institutional inflow and clinical progress offset by sustained share pressure

Capital World Investors acquired a new position in Moderna during the fourth quarter, purchasing 12,828,040 shares valued at approximately $378,299,000. Moderna completed a Phase 2 clinical trial for its maternal RSV vaccine (mRNA-1345), designed for use during pregnancy. Additional developments included UK regulatory authorization for a Phase 1/2 study of Moderna’s investigational cancer prevention vaccine mRNA-4194 in partnership with the University of Oxford, initiation of new R&D and cancer vaccine trials, efforts to expand mRNA research in Taiwan, and a 20.5% reduction in Moderna shareholdings by Letko Brosseau & Associates Inc. in the fourth quarter, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees pronounced signs of technical weakness in Moderna’s price action. He notes the stock trades under its 20-day and 50-day averages, despite institutional developments such as Capital World Investors’ recent entry. Selling pressure persists with momentum indicators firmly in negative territory and no bullish reversal signals on daily charts. Large share reductions by Letko Brosseau & Associates raise further questions about sustained demand. "Unless the price can reclaim $49.60 with conviction, risk of further downside remains the core narrative for me."

Viktoras Karapetjanc, expert at Traders Union, believes Moderna’s long-term outlook is underpinned by robust institutional interest and successful R&D milestones. He views the company’s major trial completions and new partnerships as reinforcing a bullish structure. Macro flows from recent large acquisitions and expansion into new markets support further growth potential. "With strong weekly indicator signals and persistent fundamental momentum, I expect the market to reward upward breakouts above $49.60 in the coming days."

Parshwa Turakhiya, analyst, notes a sentiment-driven setup with high volatility and mixed intraday signals for Moderna. He observes that although daily technicals suggest short-term weakness, supportive weekly indicators keep the short-term risk-reward balanced. Intraday buyer activity exists but is overshadowed by persistent downside pressure. "I see immediate opportunities for active traders within the $44.30–$49.60 band, favoring quick trades over directional bets until the next catalyst emerges."

Daily momentum weakens as session closes near lows and volatility rises

Momentum signals are weak on the daily chart: the MACD shows a strong sell reading, and the Average Directional Index (ADX) indicates a lack of a clear trend. The Relative Strength Index (RSI) and Stochastic RSI both point to a neutral-to-weak setup, while the Commodity Channel Index (CCI) is neutral. Bull/Bear Power (BBP) is positive at 0.42, signaling buyers dominate intraday action, but this is in an oversold context. The stock fell $1.31 or 2.75% on the session with a noticeable downside gap of about $0.34. Price is near the session low, and intraday volatility stands at 4.58%. There is clear downside pressure after the open and daily momentum indicators confirm the intraday bearish tone.

Earlier, analysts noted that while Moderna faced near-term headwinds, ongoing advances in its pipeline and partnerships supported a cautiously optimistic long-term view. The latest developments—including significant institutional investment, clinical progress, and heightened intraday volatility—reinforce the narrative of sustained interest amid uncertainty, making the $44.30 support level a pivotal threshold to watch for potential shifts in sentiment in the days ahead.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.